The quarter was dominated by the Faeth acquisition and private placement, already reflected in the stock. Focus on Phase 2 endometrial cancer data in H2 2026 as the next major catalyst. Monitor S-3 resale activity for potential overhang.
Price Chart
Executive Summary
Sensei Biotherapeutics reported Q1 2026 results showing a net loss of $170.2M ($131.45/share), primarily driven by a $133M acquired IPR&D charge from the Faeth Therapeutics acquisition. The company ended the quarter with $202.8M in cash, providing runway through key PIKTOR milestones including Phase 2 endometrial cancer data expected in H2 2026.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities of $202.8M as of March 31, 2026, up from $21.2M at December 31, 2025.
- Net loss of $170.2M ($131.45 per share) for Q1 2026, compared to $6.9M ($5.45 per share) in Q1 2025.
- Acquired IPR&D expenses of $133.0M from the Faeth asset acquisition.
- First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer.
- Topline Phase 2 data for PIKTOR in advanced endometrial cancer expected in second half 2026.
- S-3 filed in April 2026 registers up to 24.9M shares for resale by selling stockholders, creating potential overhang.
Financial Impact
Net loss surged to $170.2M due to $133M one-time acquired IPR&D charge; cash balance strengthened to $202.8M from $21.2M.
Risk Factors
- Overhang from S-3 registration allowing selling stockholders to exit.
- Clinical trial risk for PIKTOR in endometrial and breast cancer.
- High cash burn rate with no near-term revenue; future dilution possible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-225323 |
| Document: d125741d8k.htm | 0001193125-26-225323 |
| Document: 0001193125-26-225323-index-headers.html | 0001193125-26-225323 |
| Document: 0001193125-26-225323-index.html | 0001193125-26-225323 |
| Document: 0001193125-26-225323.txt | 0001193125-26-225323 |
| 8-K Data (Synthetic) | 0001193125-26-225323 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 19w ago | 3 | $13.86 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 8-K | $13.04 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | EFFECT | $13.04 | awaiting T+5 | — | — |
Jun 10, 2026 19w ago | S-3/A | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 10, 2026 19w ago | 8-K | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 2, 2026 21w ago | 10-K/A | $16.10 $12.63 | ▼ −21.53% | ▼ −18.56% | — |
Jun 2, 2026 21w ago | S-3/A | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
Jun 1, 2026 21w ago | Insider Cluster | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
May 22, 2026 22w ago | DEFA14A | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
May 22, 2026 22w ago | 8-K | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers